Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
OncoZenge AB (publ), a late-stage pharmaceutical company advancing its lead candidate BupiZenge™ into Phase III execution, is pleased to announce its Capital Markets Day on Thursday, 18 September 2025, in Stockholm, Sweden. The event will offer investors, analysts, and media an in-depth look at OncoZenge's strategic direction, commercial opportunities, and operational milestones.
Event Overview
The Capital Markets Day will take place from 15:00 to 17:00 CET at Redeye, Mäster Samuelsgatan 42, 10th Floor, Stockholm.
Key highlights include:
- Strategy and growth roadmap for OncoZenge
- Insights into market positioning and commercial opportunity
- Updates on execution plans for the BupiZenge™ Phase III program
- Q&A with OncoZenge's board and management
The event will be conducted in English and recorded for later on-demand viewing.
Registration Details
To attend, please register at https://crm.redeye.se/events/registration/openinvitation/701Td00000PVOHQIA5. On-site attendance is limited, so early registration is encouraged.
Networking and Engagement
Following the presentations, attendees are invited to a networking session with light refreshments, providing an opportunity to engage directly with company representatives.
Welcome!
BupiZenge™ - Potential to be the leading treatment for oral pain.
For additional information, please contact:
Stian Kildal, CEO, mobile: +46 76 115 3797, e-mail: stian.kildal@oncozenge.se
About this release
The information in this release was submitted for publication, through the agency of the contact person(s) set out above, at 16:00 CEST on August 27, 2025.
Certified Adviser
OncoZenge's Certified Adviser is Redeye AB.
OncoZenge AB
Gustavslundsvägen 34, 167 51 Stockholm, Sweden
About OncoZenge
Headquartered in Stockholm, Sweden, OncoZenge is dedicated to developing better treatments for oral pain in conditions with significant unmet needs. BupiZenge™, its lead candidate, leverages decades of clinical experience with bupivacaine to offer a safe, effective, non-opioid and well-tolerated alternative to current therapies. Learn more at: www.oncozenge.se. OncoZenge is publicly traded on Nasdaq First North Growth Market (Ticker: ONCOZ).